Thomas Elmer Witzig, MD

  • 40899 Citations
  • 109 Scopus h-Index
1976 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Thomas Elmer Witzig is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 55 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

  • Lymphoma Specialized Program of Research Excellence

    Macon, W. R., Dogan, A. M., Ansell, S. M., Gupta, M. D., Witzig, T. E., Cerhan, J. R., Habermann, T. M., Ratliff, T. L., Link, B. K., Ratliff, T. L., Juweid, M., Ballas, Z., Link, B. K., Ratliff, T., Geyer, S. M., Weiner, G., Lentz, S., Hohl, R., Smith, B. J., Kaufmann, S. H., Feldman, A. L. & Witzig, T. E.

    National Institutes of Health

    9/11/026/30/17

    Project: Research project

  • Research Output

    Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma

    Nowakowski, G. S., Chiappella, A., Witzig, T. E., Scott, D. W., Spina, M., Gascoyne, R. D., Zhang, L., Russo, J., Kang, J., Zhang, J., Xu, Y. & Vitolo, U., Jan 31 2020, In : Haematologica. 105, 2, p. E72-E75

    Research output: Contribution to journalLetter

    Open Access

    Acalabrutinib for mantle cell lymphoma

    Witzig, T. E. & Inwards, D., Jan 1 2019, In : Blood. 133, 24, p. 2570-2574 5 p.

    Research output: Contribution to journalArticle

  • 1 Scopus citations

    Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare

    Hampel, P. J., Call, T. G., Ding, W., Muchtar, E., Kenderian, S. S., Wang, Y., Leis, J. F., Witzig, T. E., Koehler, A. B., Fonder, A. L., Schwager, S. M., Rabe, K. G., Van Dyke, D. L., Braggio, E., Slager, S. L., Kay, N. E. & Parikh, S. A., Jan 1 2019, (Accepted/In press) In : American journal of hematology.

    Research output: Contribution to journalLetter

    Open Access

    Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma

    Wang, Y., Wenzl, K., Manske, M. K., Asmann, Y., Sarangi, V., Greipp, P. T., Krull, J. E., Hartert, K., He, R., Feldman, A. L., Maurer, M. J., Slager, S. L., Nowakowski, G. S., Habermann, T. M., Witzig, T. E., Link, B. K., Ansell, S. M., Cerhan, J. R. & Novak, A. J., Sep 1 2019, In : Blood cancer journal. 9, 9, 73.

    Research output: Contribution to journalArticle

    Open Access
  • Ascorbic acid–induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma

    Shenoy, N., Bhagat, T. D., Cheville, J., Lohse, C., Bhattacharyya, S., Tischer, A., Machha, V., Gordon-Mitchell, S., Choudhary, G., Wong, L. F., Gross, L. A., Ressigue, E., Leibovich, B., Boorjian, S. A., Steidl, U., Wu, X., Pradhan, K., Gartrell, B., Agarwal, B., Pagliaro, L. & 8 others, Suzuki, M., Greally, J. M., Rakheja, D., Houston Thompson, R., Susztak, K., Witzig, T. E., Zou, Y. & Verma, A., Apr 1 2019, In : Journal of Clinical Investigation. 129, 4, p. 1612-1625 14 p.

    Research output: Contribution to journalArticle

    Open Access
  • 5 Scopus citations